EYPT (EyePoint) Cyclically Adjusted Book per Share: $3.66 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EYPT EyePoint Inc EYPT
30 GF Score
Price $5.32
GF Value $0.35
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is EyePoint Cyclically Adjusted Book per Share?

EyePoint EYPT -1.48% 30 Cyclically Adjusted Book per Share is $3.66 as of Jun. 2026. GuruFocus rates EYPT with a GF Score™ of 30/100 and a GF Value™ of $0.35 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

EyePoint's adjusted book value per share for the three months ended in Jun. 2026 was $1.958. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.66 for the trailing ten years ended in Jun. 2026.

During the past 12 months, EyePoint's average Cyclically Adjusted Book Growth Rate was -10.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -8.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -7.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -44.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of EyePoint was -5.50% per year. The lowest was -80.30% per year. And the median was -17.60% per year.

As of today (2026-08-23), EyePoint's current stock price is $5.32. EyePoint's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $3.66. EyePoint's Cyclically Adjusted PB Ratio of today is 1.45.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of EyePoint was 5.82. The lowest was 0.02. And the median was 1.78.


EyePoint  (NAS:EYPT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

EyePoint's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.32/3.66
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of EyePoint was 5.82. The lowest was 0.02. And the median was 1.78.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


EyePoint Cyclically Adjusted Book per Share Related Terms


EyePoint Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for EyePoint's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Cyclically Adjusted Book per Share Chart

EyePoint Annual Data
Trend Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.22 5.10 4.95 4.40 3.91

EyePoint Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.11 3.99 3.91 3.78 3.66

EYPT vs OLMA, LXRX, ANRO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, EyePoint's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint's Cyclically Adjusted PB Ratio falls into.


EYPT
30GF Score
EyePoint Inc EYPT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EyePoint Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EyePoint's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.958/333.9520*333.9520
=1.958

Current CPI (Jun. 2026) = 333.9520.

EyePoint Quarterly Data

Book Value per Share CPI Adj_Book
201609 4.227 241.428 5.847
201612 4.319 241.432 5.974
201703 3.507 243.801 4.804
201706 3.388 244.955 4.619
201709 2.239 246.819 3.029
201712 2.188 246.524 2.964
201803 1.521 249.554 2.035
201806 1.569 251.989 2.079
201809 5.037 252.439 6.663
201812 3.946 251.233 5.245
201903 2.080 254.202 2.733
201906 2.654 256.143 3.460
201909 1.475 256.759 1.918
201912 0.761 256.974 0.989
202003 1.321 258.115 1.709
202006 0.335 257.797 0.434
202009 0.578 260.280 0.742
202012 1.022 260.474 1.310
202103 4.026 264.877 5.076
202106 3.717 271.696 4.569
202109 3.224 274.310 3.925
202112 5.438 278.802 6.514
202203 4.900 287.504 5.692
202206 4.445 296.311 5.010
202209 4.002 296.808 4.503
202212 2.827 296.797 3.181
202303 2.285 301.836 2.528
202306 1.669 305.109 1.827
202309 1.660 307.789 1.801
202312 5.430 306.746 5.912
202403 5.010 312.332 5.357
202406 4.377 314.175 4.653
202409 4.087 315.301 4.329
202412 4.929 315.605 5.216
202503 4.336 319.799 4.528
202506 3.571 322.561 3.697
202509 2.877 324.800 2.958
202512 3.696 324.054 3.809
202603 2.762 330.213 2.793
202606 1.958 333.952 1.958

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $3.66 mean?
EyePoint (EYPT) has a Cyclically Adjusted Book per Share of $3.66 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on EyePoint and its competitors.
Is EyePoint's Cyclically Adjusted Book per Share too high?
EyePoint's current Cyclically Adjusted Book per Share is $3.66. Overall, EyePoint has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Cyclically Adjusted Book per Share compare to OLMA and LXRX?
EyePoint's Cyclically Adjusted Book per Share of $3.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on EyePoint and its competitors. EyePoint's current Cyclically Adjusted Book per Share is $3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (EYPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.35, compared to a current price of $5.32 — trading 1420% above its estimated fair value. The current Cyclically Adjusted Book per Share is $3.66. EyePoint's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For EyePoint (EYPT), the current Cyclically Adjusted Book per Share is $3.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $5.32 is trading 1420% above its estimated GF Value™ of $0.35. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Cyclically Adjusted Book per Share: $3.66
  • GF Value™: $0.35 vs. price of $5.32 (1420% above fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
30GF Score

Get the complete analysis for EYPT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.32
Price
$0.35
GF Value